Natera, Inc. (NASDAQ: NTRA) has completed the acquisition of Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection.
Foresight's patented PhasED-Seq™ technology offers unmatched sensitivity with LOD95 of 0.3 parts per million and detection below 0.1 ppm.
The strategic acquisition accelerates Natera's expansion into lymphoma and enhances its personalized MRD testing capabilities.
Cutting-edge Technology
Foresight's PhasED-Seq™ technology provides unparalleled sensitivity for MRD detection, enhancing Natera's testing capabilities.
Strategic Synergy
The acquisition combines Natera's infrastructure with Foresight's leadership in lymphoma, promising accelerated MRD adoption in solid tumor types.
Financial Details
The acquisition was an all-stock transaction totaling $275 million upfront, with potential additional earnings tied to revenue and milestones.
- The integration of phased variants into Natera's Signatera™ platform strengthens MRD testing performance across solid tumors.
- Foresight's leadership in lymphoma research complements Natera's existing product portfolio, opening new avenues for innovative diagnostic solutions.
Natera's acquisition of Foresight Diagnostics marks a significant milestone in advancing precision oncology and personalized MRD testing, positioning the company for continued growth and impact in the healthcare industry.